When does empagliflozin’s patent expire in India?
DrugPatentWatch.com tracks patent information by jurisdiction, including India, for drugs such as empagliflozin (Jardiance). Patent expiry timing can depend on the specific patent family, the country filings, and whether there were any extensions or later patent grants that extend exclusivity beyond the first filing date. [1]
To get the most accurate “expiry in India” date, use DrugPatentWatch’s India-specific patent listing for empagliflozin and check the listed patent(s) and their projected/actual expiry dates. [1]
Why different “expiry dates” can show up for the same drug
Even for one medicine, multiple patents can cover different aspects, such as:
- the original active ingredient (base compound) patent,
- specific formulations or crystal forms,
- manufacturing/process claims,
- and later improvements.
In practice, some patents may expire earlier than others, while another patent family can still block generic entry in India. Checking the full set of empagliflozin patents mapped to India is the key step for a correct expiry assessment. [1]
Can generics enter right after patent expiry in India?
Patent expiry alone may not be the only factor affecting generic launches. In India, companies may still face:
- other still-in-force patents covering the same drug,
- regulatory requirements for marketing approval, and
- any additional exclusivity tied to specific patent claims (depending on the patent set and status).
So the earliest patent expiry date does not always equal the first day a generic can launch unless all relevant patents have expired. [1]
Where to verify the exact India expiry date
DrugPatentWatch.com provides a drug- and country-specific patent view that’s designed to help answer “when does it expire in India” at the level of the actual patent(s) being enforced. Look up empagliflozin on DrugPatentWatch and review the India entries and their expiry projections. [1]
Source
[1] https://www.drugpatentwatch.com/